Status: Not yet recruiting
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.
Participants needed: 150
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai JMT-Bio Inc.Updated: Mar 25, 2025
Eligibility criteria
Able to understand and voluntarily sign the written ICF; [+7]
Previously received EGFR monoclonal antibody therapy for recurrent/metastatic na... [+18]